Akeega access in Egypt: the EDA personal-importation pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Akeega is a fixed-dose combination oral tablet from Janssen Biotech (a Johnson and Johnson company) containing niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor that blocks androgen biosynthesis. The US Food and Drug Administration approved Akeega in August 2023 for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), with a December 2025 label extension to BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). BRCA testing through an FDA-approved companion diagnostic is mandatory before initiation. In Egypt, Akeega is not yet registered as a locally marketed product through the Egyptian Drug Authority (EDA), and patients managed at the country's oncology centres who have completed BRCA testing and have a treating oncologist's plan for PARP-plus-androgen-axis combination therapy look for a structured legal route to obtain it. That route is the EDA personal-importation framework, filed through a licensed dispensing institution by the treating oncologist.

Reserved for you.

Why Egyptian patients need Akeega via the named-patient pathway

BRCA testing infrastructure in Egypt has improved substantially over the past five years, with germline and somatic BRCA panels available at Kasr Al Ainy molecular medicine services, the Children's Cancer Hospital Egypt 57357 Personalized Medication Management Unit (the first pharmacogenetics unit of its kind in Egypt and the Arab world), and several private referral laboratories. Patients with metastatic prostate cancer whose tumor has tested positive for a deleterious BRCA1 or BRCA2 mutation arrive at the Akeega prescription decision through their treating oncologist, frequently in coordination with international expert second opinions. The clinical case for PARP-plus-androgen-axis combination therapy in BRCA-mutated mCRPC rests on the MAGNITUDE trial, and the single fixed-dose tablet simplifies administration relative to running niraparib (Zejula) and abiraterone (Zytiga) as two separate prescriptions on two separate adherence schedules.

The structural reason patients reach for the EDA personal-importation pathway is direct: Akeega is not on the EDA registration list as a fixed-dose combination. Separate niraparib (Zejula) and separate abiraterone (Zytiga and generics) may be available in Egypt with varying availability, but the combination tablet is not stocked. Patients and their oncologists who prefer the single tablet for adherence reasons (an important consideration in a setting where the patient is managing other prostate cancer therapy elements at the same time) pursue named-patient import for the combination product specifically.

The EDA personal-importation pathway for Akeega

The Egyptian Drug Authority was created by Law No. 151 of 2019, with executive regulations issued by Prime Minister Decision No. 777 of 2020. EDA permits the importation of unregistered medicines for a specific named patient where no equivalent registered product is available locally, or where the available alternative cannot meet the patient's clinical need. The framework, sometimes described as Special Access or Compassionate Use for unregistered drugs, is filed through the dispensing institution's import pharmacy.

A complete Akeega application typically includes:

• A clinical justification letter from the treating oncologist, on hospital letterhead, with original signature and stamp, stating the diagnosis (mCRPC or mCSPC), the documented BRCA1 or BRCA2 mutation status from an FDA-approved companion diagnostic such as FoundationOne CDx (with the laboratory report referenced in the patient file), the prior therapies attempted (typically including androgen deprivation therapy and prior systemic regimens for mCRPC patients), and the specific clinical reason the fixed-dose combination is the appropriate next step rather than separate niraparib plus abiraterone
• The treating physician's Egyptian Medical Syndicate membership number and Ministry of Health licence reference
• A recent prescription specifying brand name (Akeega), generic name (niraparib plus abiraterone acetate), strength (100 mg niraparib plus 500 mg abiraterone acetate per tablet, two tablets daily to deliver the 200 mg plus 1,000 mg daily dose), and quantity required for the planned treatment cycle
• Patient identifier: copy of the national ID card or passport
• Full product details: manufacturer (Janssen Biotech, a Johnson and Johnson company), country of origin, FDA approval reference, shelf life, controlled-room-temperature storage class (20 to 25 degrees C with excursions permitted 15 to 30 degrees C)
• Destination dispensing facility licence (the hospital pharmacy or licensed importer pharmacy that will physically receive and dispense the tablets)
• Chain-of-custody plan covering air freight from US source through Cairo International Airport, customs clearance, and last-mile transfer to the dispensing facility, with attention to summer heat-excursion risk during Arabian Peninsula transit corridors and the requirement to keep tablets in original sealed manufacturer packaging for DSCSA traceability

For Akeega, the clinical justification letter benefits from a clear statement that BRCA testing was performed through an FDA-approved companion diagnostic (with the laboratory report and the specific mutation in the patient file), the patient's prior-line treatment history with prednisone co-administration confirmed, the proposed once-daily dosing on an empty stomach (no food for at least 1 hour before or 2 hours after each dose, per the FDA label, because of the abiraterone food-effect interaction), and the planned monitoring schedule (complete blood count weekly for the first month then monthly, blood pressure, liver function tests, serum potassium, and long-term vigilance for MDS and AML). Routine EDA personal-import authorisations for well-documented oncology cases are typically processed within a 3 to 6 week window, though complex cases extend beyond that range.

Where Akeega gets dispensed in Egypt

Akeega is an oral solid-dose product, which broadens the institutional set that can handle the case relative to cold-chain biologics. The Egyptian institutions that routinely handle named-patient oncology cases with established import pharmacy infrastructure include Cairo University Hospitals (Kasr Al Ainy), the oldest and largest academic hospital network in Egypt and the Middle East, with dedicated oncology services and the Kasr Al Ainy Centre of Clinical Oncology; Ain Shams University Hospitals, the second major academic hospital network in Cairo with strong oncology services; and on the private side Dar Al Fouad Hospital in 6th of October City (Alameda Healthcare Group, JCI-accredited since 2005, with active oncology and over 250 bone marrow transplants), As-Salam International Hospital in Cairo, and the Cleopatra Hospitals Group facilities.

Children's Cancer Hospital Egypt 57357 is pediatric-focused; adult prostate-cancer cases route through the adult oncology services at the institutions listed above. For patients in Alexandria, the practical pattern is co-management with a Cairo-based medical oncologist while the dispensing pharmacy remains at the local hospital with the import-pharmacy infrastructure to receive the EDA-authorised shipment. Smaller regional hospitals typically route through one of the Cairo centres or through a licensed specialty importer in Cairo.

Real cost picture for Akeega in Egypt

Reserve Meds quotes patients in USD and accepts USD wire transfers. The Egyptian pound has lost more than 70 percent of its value against the US dollar since early 2022, with the USD/EGP rate near 52 to 53 in May 2026 per Trading Economics historical data, and a controlled-depreciation outlook through end of year per IMF Article IV consultation forecasts. Quoting in USD insulates the patient from intra-case EGP drift between quote and shipment.

The Akeega US wholesale acquisition cost is approximately USD 19,193.60 for a 60-tablet bottle of the 100 mg niraparib plus 500 mg abiraterone acetate strength, based on published 2024 pricing references. The daily dose requires two tablets of the 100 plus 500 mg strength to deliver the labeled 200 mg niraparib plus 1,000 mg abiraterone acetate daily, which places patient-month cost in the US specialty channel at approximately USD 19,000 to 20,000 per 30-day supply at WAC before any discounts. Canadian list-price equivalents calculated by CADTH placed the 28-day cost near CAD 8,283. International pricing is highly variable.

International ambient-class logistics from US source to Cairo International Airport typically run USD 400 to 1,000 per shipment, lower than cold-chain biologics because the tablets ship at controlled room temperature with documented temperature logging. EDA permit administrative fees on the Egyptian side vary by dispensing facility and importer. Reserve Meds itemises the US-side drug procurement, the international logistics, and the concierge coordination fee separately on every firm quote.

Local payer reality is cash-dominant for named-patient oncology imports. UHIA does not currently cover most specialty imports. Private insurers operating in Egypt (Bupa Egypt, AXA Egypt, MetLife Egypt, Allianz Egypt, Misr Insurance) assess oncology named-patient claims case by case. We do not promise coverage. Many Egyptian families coordinate USD funds from relatives in the Gulf, the UK, or North America for sustained oncology cases on a planned cycle cadence.

Typical timeline for Akeega in Egypt

For a routine Egypt Akeega case with a complete documentation package (including the BRCA companion-diagnostic report), EDA personal-import authorisation typically lands in 3 to 6 weeks. The ambient-temperature handling class shortens the operational timeline by 2 to 3 days compared with cold-chain biologics because the tablets do not require validated 2 to 8 degree Celsius packaging, though summer heat-excursion mitigation is part of the chain-of-custody plan. First-time imports of a novel oral oncology combination can add 1 to 2 weeks for institutional pharmacy onboarding at the dispensing facility. Once the first cycle is in place, subsequent monthly or 28-day refill shipments follow the same chain on a planned cadence, with treatment continuing until radiographic progression or unacceptable toxicity per the FDA label.

What your physician needs to provide

The clinical justification letter is the cornerstone of the EDA application. For Akeega the strongest letters consistently include the diagnosis (mCRPC or mCSPC per the relevant FDA-approved label), the documented BRCA1 or BRCA2 mutation status from an FDA-approved companion diagnostic with the laboratory report in the patient file, the prior treatment history with androgen deprivation therapy and any prior systemic regimens, the proposed once-daily dosing of 200 mg niraparib plus 1,000 mg abiraterone acetate on an empty stomach with prednisone 10 mg orally once daily co-administered, the planned monitoring schedule (complete blood count weekly for the first month then monthly, blood pressure, liver function tests, serum potassium, cortisol monitoring if adrenal insufficiency is suspected, and long-term vigilance for MDS and AML given the PARP-class warning), and the treating physician's EMS membership and MoH licence references.

The treating physician retains the clinical decision and the pharmacovigilance reporting obligation through the Egyptian Pharmacovigilance Center (EPVC). Reserve Meds supplies the documentation template and the chain-of-custody packet from the US side; we do not write the clinical letter, do not advise on the Akeega-versus-olaparib-plus-abiraterone-versus-talazoparib-plus-enzalutamide choice, and do not direct dosing.

Common questions about Akeega in Egypt

Will Bupa Egypt, AXA Egypt, MetLife, or Allianz cover Akeega?

Each insurer assesses named-patient oncology imports case by case. Some plans reimburse a percentage when the drug treats a covered indication even if the specific product is not on a local formulary; many require pre-authorisation. We do not promise coverage. We supply the documentation set that allows your insurer to assess, and the claim sits with the patient or the dispensing hospital.

What is the safety profile we should be aware of?

The most common adverse reactions in the MAGNITUDE trial were anemia, hypertension, fatigue, constipation, nausea, and musculoskeletal pain. PARP-class hematologic toxicity (anemia, thrombocytopenia, neutropenia) is the principal acute concern. Myelodysplastic syndrome and acute myeloid leukemia have been reported with niraparib and other PARP inhibitors, including fatal cases, and the FDA label carries that warning. Abiraterone contributes hypertension, hypokalemia, fluid retention, and adrenocortical insufficiency under stress conditions.

Why the combination tablet versus separate niraparib and abiraterone?

A single fixed-dose tablet simplifies administration and adherence relative to two separately prescribed and separately sourced medicines. Separate niraparib (Zejula) and separate abiraterone (Zytiga and generics) may be available in Egypt with varying stocking; the combination tablet is not. The treating oncologist makes the clinical call on whether the single-tablet adherence benefit justifies the named-patient route.

Is Akeega a controlled substance?

No. Akeega is not on any DEA schedule. Reserve Meds coordinates Akeega imports under the standard EDA personal-importation framework.

How long do we stay on therapy?

Per the FDA label, treatment continues until radiographic disease progression or unacceptable toxicity. There is no fixed treatment duration in the label. The treating oncologist sets the goals of care and the discontinuation criteria with the patient and family.

Our family is split between Cairo and the Gulf. Can you coordinate in both places?

Yes. Reserve Meds runs patient-side coordination in Arabic where requested and family-side coordination in English in parallel, with a single named coordinator running the case end to end across the Egyptian diaspora.

Where Reserve Meds fits in Akeega cases

Reserve Meds is a US-based concierge coordinator. We do not replace your oncologist, do not replace EDA, do not replace your dispensing pharmacy, and do not act as an importer of record in Egypt. What we do is orchestrate the US-side specialty channel sourcing through the Janssen authorized network (including specialty distributors such as Onco360), prepare the documentation kit your physician needs for the EDA personal-import filing with the BRCA companion-diagnostic report referenced, coordinate the international ambient-class logistics to Cairo International Airport with documented temperature logging and heat-excursion mitigation, and run a single named concierge throughout the case. Akeega has no prior Reserve Meds case experience as of this review under the August 2023 mCRPC label, so the operating posture is standard NPP coordination with particular attention to the BRCA documentation prerequisite, customs declarations that explicitly name the indication so reviewers do not mischaracterize the shipment, and continuity of supply across the monthly refill cycle.

Next step

If you or a family member has BRCA-mutated metastatic prostate cancer and your treating oncologist is considering Akeega, add the case to the waitlist with the BRCA report ready to share. We will respond within 24 to 48 hours with a documentation kit for your physician and an indicative USD cost range.

Reserved for you.

---

This guide is informational, not medical or legal advice. The EDA personal-importation framework requires a licensed Egyptian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.